Previous 10 | Next 10 |
2023-11-07 12:51:35 ET Gainers: PaxMedica ( PXMD ) +78% . Jaguar Global Growth Corp I ( JGGC ) +62% . Transmedics Group ( TMDX ) +54% . Baiyu Holdings ( BYU ) +48% . Fathom Digital Manufacturing Corporation ( FATH ) +46% . Ko...
2023-11-07 11:45:16 ET Summary Today, we look at Ventyx Biosciences, Inc., a clinical-stage biopharma company focused on developing small molecule products for inflammatory diseases. The company has now had two major trial disappointments in the span of a month, triggering a huge ...
2023-11-07 08:36:07 ET Losers: Ventyx Biosciences ( VTYX ) -76% announces results from the phase 2 trial of VTX958 in patients with moderate to severe plaque Psoriasis and provides corporate update. Alto Ingredients ( ALTO ) -50% reports third quarter 2023 re...
2023-11-07 05:25:09 ET Related stories Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript Alteryx, Inc. (AYX) Q3 2023 Earnings Call Transcript TransMedics Group, Inc. (TMDX) Q3 2023 Earnings Call Transcript The S&P 500's Market Regime Reest...
2023-11-06 17:38:29 ET Gainers: TransMedics ( TMDX ) +35% . EverQuote ( EVER ) +20% . Vimeo ( VMEO ) +13% . TaskUs ( TASK ) +13% . TripAdvisor ( TRIP ) +11% . Losers: Ventyx Biosciences ( VTYX ) -74% ....
2023-11-06 17:03:58 ET More on Ventyx Biosciences Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript Ventyx stock plunges following Phase 2 results for ulcerative colitis drug ...
VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16 Efficacy results did not meet the internal target to support further development of VTX958 in psoriasis; Ventyx to terminate Phase 2 trials...
Ventyx Biosciences Inc. (VTYX) is expected to report $-0.88 for Q3 2023
2023-10-11 16:49:40 ET More on Ventyx Biosciences Ventyx stock plunges following Phase 2 results for ulcerative colitis drug Seeking Alpha’s Quant Rating on Ventyx Biosciences Historical earnings data for Ventyx Biosciences For further details see: ...
2023-10-10 13:10:42 ET More on 5E Advanced Materials 5E Advanced Materials, Inc. (FEAM) Q4 2023 Earnings Call Transcript 5E Advanced Materials hires new contractors to complete small scale boron facility Seeking Alpha’s Quant Rating on 5E Advanced Materials ...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...